Aarvik Therapeutics
Stuart Lutzker is a distinguished professional in the biopharmaceutical industry, currently serving as President and Co-Founder of Arrivent Biopharma since June 2021. Prior to this role, Stuart held the position of Vice President of gRED Oncology Early Clinical Development at Genentech from 2004 to May 2021. Stuart's academic background includes an MD-PhD in Biochemistry from Columbia University Vagelos College of Physicians and Surgeons, completed between 1983 and 1990, and a Bachelor of Arts degree from Columbia University attained from 1979 to 1983.
This person is not in any teams
Aarvik Therapeutics
Aarvik Therapeutics is pursuing exciting, novel molecules with an improved therapeutic index for several oncology targets by combining a novel modular antibody platform with multiple target mechanisms.